PharmaBoardroom

Moving the Needle on Gender Diversity in Swiss Pharma Leadership

While Switzerland has Europe's second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and…

Utilising Data-Science to Boost US Market Access in Volatile…

Dr Philipp Diesinger and Dr Gabriell Máté outline why a data-driven approach can help optimise patient copay assistance programs in the US across a…

LatAm: Big Indian Investment; Argentina’s COVID-19 Woes;…

The latest from healthcare and the life sciences in Latin America, including the most recent wave of Indian pharma investment; Argentina’s ongoing…

MEA Roundup: Turkey’s Pharma Debt; Saudi Market Rise; UAE…

A roundup of the latest from the Middle East & Africa region, including Turkey’s debt to US pharma; deals between Saudi SPIMACO and Janssen, Abu…

Fosun Pharma Gearing Up to Bring mRNA COVID-19 Vaccine to China

The collaboration between BioNTech and Pfizer on a COVID-19 vaccine candidate based on mRNA technology continues apace, with hopes for an emergency…

The German Biotech Behind Pfizer’s COVID-19 Vaccine Candidate

German biotech BioNTech has been thrust into the global spotlight thanks to its collaboration with global giant Pfizer on a COVID-19 vaccine. The…

Katharina Gasser – Managing Director, Biogen Switzerland…

Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why…

Asia-Pacific: Hiring the Right Healthtech CFO Can Be Tough; It…

Robert Hall of Hong Kong-based executive recruitment specialist Ardent Search highlights the key traits and experiences that Asian biotech and medtech…

China: The Pharma Deals Keep Coming

The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio…

Market Access in Switzerland: Reimbursement Delays for 76% of New…

Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to…

Biosimilar Adoption in the US: Still Lagging Behind Europe

As part of our upcoming US Healthcare and Life Sciences Review, we spoke to key stakeholders – former Association for Accessible Medicines (AAM)…

Chinese Biotech Strategies: Biologics or Small Molecules

While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception…

Tagged with BI